Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Cyclodextrin Reduces Cholesterol Crystal-Induced Inflammation by Modulating Complement Activation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Collagen VI Contains Multiple Host Defense Peptides with Potent In Vivo Activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Multiple Homozygous Variants in the STING-Encoding TMEM173 Gene in HIV Long-Term Nonprogressors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Antibody-Mediated Neutralization of uPA Proteolytic Function Reduces Disease Progression in Mouse Arthritis Models

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Amyotrophic lateral sclerosis and the innate immune system: protocol for establishing a biobank and statistical analysis plan

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Fatal pneumococcus meningitis in a child with complement factor ficolin-3 deficiency

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  3. Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel Batokine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Siril S Bakke
  • Marie H Aune
  • Nathalie Niyonzima
  • Katrine Pilely
  • Liv Ryan
  • Mona Skjelland
  • Peter Garred
  • Pål Aukrust
  • Bente Halvorsen
  • Eicke Latz
  • Jan K Damås
  • Tom E Mollnes
  • Terje Espevik
Vis graf over relationer

Cholesterol crystals (CC) are abundant in atherosclerotic plaques and promote inflammatory responses via the complement system and inflammasome activation. Cyclic oligosaccharide 2-hydroxypropyl-β-cyclodextrin (BCD) is a compound that solubilizes lipophilic substances. Recently we have shown that BCD has an anti-inflammatory effect on CC via suppression of the inflammasome and liver X receptor activation. The putative effects of BCD on CC-induced complement activation remain unknown. In this study, we found that BCD bound to CC and reduced deposition of Igs, pattern recognition molecules, and complement factors on CC in human plasma. Furthermore, BCD decreased complement activation as measured by terminal complement complex and lowered the expression of complement receptors on monocytes in whole blood in response to CC exposure. In line with this, BCD also reduced reactive oxygen species formation caused by CC in whole blood. Furthermore, BCD attenuated the CC-induced proinflammatory cytokine responses (e.g., IL-1α, MIP-1α, TNF, IL-6, and IL-8) as well as regulated a range of CC-induced genes in human PBMC. BCD also regulated complement-related genes in human carotid plaques treated ex vivo. Formation of terminal complement complex on other complement-activating structures such as monosodium urate crystals and zymosan was not affected by BCD. These data demonstrate that BCD inhibits CC-induced inflammatory responses, which may be explained by BCD-mediated attenuation of complement activation. Thus, these findings support the potential for using BCD in treatment of atherosclerosis.

TidsskriftJournal of immunology (Baltimore, Md. : 1950)
Udgave nummer8
Sider (fra-til)2910-2920
Antal sider11
StatusUdgivet - 15 okt. 2017

ID: 52367722